Research advances and new challenges in overcoming triple-negative breast cancer

Abstract

Triple-negative breast cancer (TNBC) is a pathological term used to identify invasive breast cancers that lack expression of estrogen and progesterone receptors and do not have pathologic overexpression of the HER2 receptor or harbor ERBB2 gene amplification. TNBC includes a collection of multiple distinct disease entities based upon genomic, transcriptomic and phenotypic characterization. Despite improved clinical outcomes with the development of novel therapeutics, TNBC still yields the worst prognosis among all clinical subtypes of breast cancer. We will systematically review evidence of the genomic evolution of TNBC, as well as potential mechanisms of disease progression and treatment resistance, defined in part by advances in next-generation DNA sequencing technology (including single cell sequencing), providing a new perspective on treatment strategies, and promise to reveal new potential therapeutic targets. Moreover, we review novel therapies aimed at homologous recombination deficiency, PI3 kinase/AKT/PTEN pathway activation, androgen receptor blockade, immune checkpoint inhibition, as well as antibody-drug conjugates engaging novel cell surface targets, including recent progress in pre-clinical and clinical studies which further validate the role of targeted therapies in TNBC. Despite major advances in treatment for TNBC, including FDA approval of 2 PARP inhibitors for metastatic TNBC, the crossing of the superiority boundary in a phase 3, placebo-controlled study of adjuvant olaparib in early-stage patients with germline BRCA-mutated high-risk HER2-negative early breast cancer, the FDA approval of 2 PD-(L)1 checkpoint antibodies for metastatic TNBC, and the FDA approval of the first antibody drug conjugate for TNBC, significant challenges remain. For example, despite the dawn of immunotherapy in metastatic TNBC, durable responses are limited to a small subset of patients, definitive biomarkers for patient selection are lacking, and the Oncology Drug Advisory Committee to the FDA has recently voted against approval of an anti-PD-1 checkpoint antibody high risk early-stage TNBC in the neoadjuvant setting. Also, despite early positive randomized phase 2 studies of AKT inhibition in metastatic TNBC, a recent phase 3 registration trial failed to validate earlier phase 2 data. Finally, we note that level one evidence for clinical efficacy of androgen receptor blockade in TNBC is still lacking. To meet these and other challenges, we will catalogue the ongoing exponential increase in interest in basic, translational, and clinical research to develop new treatment paradigms for TNBC.

Keywords

Triple negative breast cancer / subtypes / genomic evolution / therapeutic targets / homologous recombination deficiency / antibody-drug conjugates / immunotherapy / tumor immune microenvironment

References

[1] Perou CM,Eisen MB.Molecular portraits of human breast tumours.Nature2000;406:747-52

[2] Wang C,Lai X.Triple negative breast cancer in Asia: An insider's view.Cancer Treat Rev2018;62:29-38

[3] Thakur KK,Kunnumakkara AB.Alarming burden of triple-negative breast cancer in India.Clin Breast Cancer2018;18:e393-9

[4] Wolff AC,Allison KH.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.Arch Pathol Lab Med2018;142:1364-82

[5] Hammond ME,Dowsett M.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.J Clin Oncol2010;28:2784-95 PMCID:PMC2881855

[6] Foulkes WD,Reis-Filho JS.Triple-negative breast cancer.N Engl J Med2010;363:1938-48

[7] Liedtke C,Hess KR.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol2008;26:1275-81

[8] Carey LA,Sawyer L.The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res2007;13:2329-34

[9] Lin NU,Hughes ME.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.Cancer2012;118:5463-72 PMCID:PMC3611659

[10] Dent R,Pritchard KI.Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res2007;13:4429-34

[11] Cortazar P,Untch M.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet2014;384:164-72

[12] von Minckwitz G,Loibl S.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Lancet Oncol2014;15:747-56

[13] Sikov WM,Perou CM.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).J Clin Oncol2015;33:13-21 PMCID:PMC4268249

[14] Herschkowitz JI,Weigman VJ.Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.Genome Biol2007;8:R76 PMCID:PMC1929138

[15] Prat A,Karginova O.Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.Breast Cancer Res2010;12:R68 PMCID:PMC3096954

[16] Prat A.Deconstructing the molecular portraits of breast cancer.Mol Oncol2011;5:5-23 PMCID:PMC5528267

[17] Lehmann BD,Chen X.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest2011;121:2750-67 PMCID:PMC3127435

[18] Masuda H,Wang Y.Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.Clin Cancer Res2013;19:5533-40 PMCID:PMC3813597

[19] Lehmann BD,Chen X.Refinement of Triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection.PLoS One2016;11:e0157368 PMCID:PMC4911051

[20] Burstein MD,Poage GM.Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.Clin Cancer Res2015;21:1688-98 PMCID:PMC4362882

[21] Koboldt DC,Larson DE.The next-generation sequencing revolution and its impact on genomics.Cell2013;155:27-38 PMCID:PMC3969849

[22] Shah SP,Goya R.The clonal and mutational evolution spectrum of primary triple-negative breast cancers.Nature2012;486:395-9 PMCID:PMC3863681

[23] Wang Y,Leung ML.Clonal evolution in breast cancer revealed by single nucleus genome sequencing.Nature2014;512:155-60 PMCID:PMC4158312

[24] Yates LR,Knappskog S.Subclonal diversification of primary breast cancer revealed by multiregion sequencing.Nat Med2015;21:751-9 PMCID:PMC4500826

[25] Gao R,McDonald TO.Punctuated copy number evolution and clonal stasis in triple-negative breast cancer.Nat Genet2016;48:1119-30 PMCID:PMC5042845

[26] Sottoriva A,Ma Z.A Big Bang model of human colorectal tumor growth.Nat Genet2015;47:209-16 PMCID:PMC4575589

[27] Williams MJ,Barnes CP.Identification of neutral tumor evolution across cancer types.Nat Genet2016;48:238-44 PMCID:PMC4934603

[28] Ng C,Piscuoglio S.Genetic heterogeneity in therapy-naïve synchronous primary breast cancers and their metastases.Clin Cancer Res2017;23:4402-15 PMCID:PMC5768571

[29] Bertucci F,Patsouris A.Genomic characterization of metastatic breast cancers.Nature2019;569:560-4

[30] Angus L,Wilting SM.The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.Nat Genet2019;51:1450-8 PMCID:PMC6858873

[31] Nik-Zainal S,Staaf J.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Nature2016;534:47-54 PMCID:PMC4910866

[32] Balko JM,Vaught DB.Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.Nat Med2012;18:1052-9 PMCID:PMC3693569

[33] Almendro V,Randles A.Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.Cell Rep2014;6:514-27 PMCID:PMC3928845

[34] Al-Hajj M,Benito-Hernandez A.Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci U S A2003;100:3983-8 PMCID:PMC153034

[35] Wright MH,Herschkowitz JI.Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.Mol Cancer2008;7:29 PMCID:PMC2329667

[36] Kim C,Sei E.Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing.Cell2018;173:879-93.e13 PMCID:PMC6132060

[37] O'Shaughnessy J,Cazzaniga M.Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.Breast Cancer Res2020;22:114 PMCID:PMC7590609

[38] Sharma P,Kimler BF.Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Breast Cancer Res Treat2014;145:707-14 PMCID:PMC4171847

[39] Ray Chaudhuri A,Ding X.Replication fork stability confers chemoresistance in BRCA-deficient cells.Nature2016;535:382-7 PMCID:PMC4959813

[40] Hahnen E,Hauke J.Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the GeparSixto randomized clinical trial.JAMA Oncol2017;3:1378-85 PMCID:PMC5710508

[41] Tutt A,Cheang M.Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med2018;24:628-37 PMCID:PMC6372067

[42] Robson M,Senkus E.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.N Engl J Med2017;377:523-33

[43] IDMC has concluded that OlympiA trial of Lynparza crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/olympia-trial-of-lynparza-idmc-recommend-early-analysis.html [Last accessed on 24 Mar 2021]

[44] Silver DP,Eklund AC.Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.J Clin Oncol2010;28:1145-53 PMCID:PMC2834466

[45] Akashi-Tanaka S,Takamaru T.BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.Clin Breast Cancer2015;15:80-5

[46] Winter C,Olsson E.Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.Ann Oncol2016;27:1532-8 PMCID:PMC4959927

[47] Abkevich V,Hennessy BT.Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.Br J Cancer2012;107:1776-82 PMCID:PMC3493866

[48] Birkbak NJ,Kim JY.Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.Cancer Discov2012;2:366-75 PMCID:PMC3806629

[49] Popova T,Rieunier G.Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.Cancer Res2012;72:5454-62

[50] Davies H,Morganella S.HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.Nat Med2017;23:517-25 PMCID:PMC5833945

[51] Esteller M,Dominguez G.Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.J Natl Cancer Inst2000;92:564-9

[52] Saal LH,Persson C.Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.Nat Genet2008;40:102-7 PMCID:PMC3018354

[53] Turner NC,Russell AM.BRCA1 dysfunction in sporadic basal-like breast cancer.Oncogene2007;26:2126-32

[54] Timms KM,Hughes E.Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.Breast Cancer Res2014;16:475 PMCID:PMC4308910

[55] Mayer EL,Jankowitz R.TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Ann Oncol2020;31:1518-25

[56] Telli ML,Timms K.Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.J Clin Oncol2018;36:519

[57] Loibl S,Timms KM.Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.Ann Oncol2018;29:2341-7

[58] Telli ML,Audeh W.Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.Breast Cancer Res Treat2018;168:625-30

[59] Telli ML,Reid J.Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer.Clin Cancer Res2016;22:3764-73 PMCID:PMC6773427

[60] Staaf J,Bosch A.Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.Nat Med2019;25:1526-33 PMCID:PMC6859071

[61] Chopra N,Pearson A.Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.Nat Commun2020;11:2662 PMCID:PMC7260192

[62] Gulhan DC,Melloni GEM.Detecting the mutational signature of homologous recombination deficiency in clinical samples.Nat Genet2019;51:912-9

[63] Quereda V,Vena F.Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer.Cancer Cell2019;36:545-58.e7

[64] Cantley LC.The phosphoinositide 3-kinase pathway.Science2002;296:1655-7

[65] Genome Atlas Network. Comprehensive molecular portraits of human breast tumours.Nature2012;490:61-70 PMCID:PMC3465532

[66] Curtis C,Chin SF.The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.Nature2012;486:346-52 PMCID:PMC3440846

[67] Schmid P,Chan S.Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial.J Clin Oncol2020;38:423-33

[68] Takeshita T,Yamamoto-Ibusuki M.Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.Mol Cancer2018;17:67 PMCID:PMC6389169

[69] Yuan H,Liu Y.Association of PIK3CA mutation status before and after neoadjuvant chemotherapy with response to chemotherapy in women with breast cancer.Clinical Cancer Research2015;21:4365-72

[70] Bareche Y,Ignatiadis M.Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.Ann Oncol2018;29:895-902 PMCID:PMC5913636

[71] Kim SB,Im SA.Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol2017;18:1360-72 PMCID:PMC5626630

[72] Dent R,Oliveira M.Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. Proceedings of the 2020 Virtual San Antonio Breast Cancer Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; 2021.

[73] Verma S,Gianni L.Trastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med2012;367:1783-91 PMCID:PMC5125250

[74] von Minckwitz G,Mano MS.Trastuzumab emtansine for residual invasive HER2-positive breast cancer.N Engl J Med2019;380:617-28

[75] Modi S,Yamashita T.Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer.N Engl J Med2020;382:610-21 PMCID:PMC7458671

[76] Bardia A,Vahdat LT.Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer.N Engl J Med2019;380:741-51

[77] Sacituzumab govitecan package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf. [Last accessed on 24 Mar 2021]

[78] Bardia A,Loirat D.ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC).Ann Oncol2020;31:S1149-50

[79] Hurvitz SA,Punie K.Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.San Antonio Breast Cancer Symposium2020;

[80] Han H,Alemany C. Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, USA. 2020.

[81] Ogitani Y,Oitate M.Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.Cancer Sci2016;107:1039-46 PMCID:PMC4946713

[82] Ogitani Y,Hagihara K.DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res2016;22:5097-108

[83] Modi S,Murthy RK.Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study.J Clin Oncol2020;38:1887-96 PMCID:PMC7280051

[84] Banerji U,Saura C.Trastuzumab duocarmazine in locally advanced and metastatic solid tumors and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study.Lancet Oncol2019;20:1124-35

[85] Tolcher AW.The evolution of antibody-drug conjugates: A positive inflexion point.Am Soc Clin Oncol Educ Book2020;40:1-8

[86] Doane AS,Lal P.An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.Oncogene2006;25:3994-4008

[87] Loibl S,von Minckwitz G.Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.Breast Cancer Res Treat2011;130:477-87

[88] Cochrane DR,Jacobsen BM.Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.Breast Cancer Res2014;16:R7 PMCID:PMC3978822

[89] Jia LY,Sethi G.Potential role of targeted therapies in the treatment of triple-negative breast cancer.Anticancer Drugs2016;27:147-55

[90] Gucalp A,Isakoff SJ.Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer.Clin Cancer Res2013;19:5505-12 PMCID:PMC4086643

[91] Bonnefoi H,Tredan O.A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).Ann Oncol2016;27:812-8

[92] Traina TA,Yardley DA.Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer.J Clin Oncol2018;36:884-90 PMCID:PMC5858523

[93] Schumacher TN.Neoantigens in cancer immunotherapy.Science2015;348:69-74

[94] Ahn J,Rabasa Capote A.Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells.Cancer Cell2018;33:862-73.e5 PMCID:PMC6177226

[95] Sharma P.The future of immune checkpoint therapy.Science2015;348:56-61

[96] Loi S,Adams S.Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers.J Clin Oncol2019;37:559-69 PMCID:PMC7010425

[97] Topalian SL,Pardoll DM.Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell2015;27:450-61 PMCID:PMC4400238

[98] Karn T,Hatzis C.Association between genomic metrics and immune infiltration in triple-negative breast cancer.JAMA Oncol2017;3:1707-11 PMCID:PMC5824276

[99] Dushyanthen S,Savas P.Relevance of tumor-infiltrating lymphocytes in breast cancer.BMC Med2015;13:202 PMCID:PMC4547422

[100] Azizi E,Plitas G.Single-cell map of diverse immune phenotypes in the breast tumor microenvironment.Cell2018;174:1293-308.e36 PMCID:PMC6348010

[101] Chung W,Lee HO.Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.Nat Commun2017;8:15081 PMCID:PMC5424158

[102] Wagner J,Chevrier S.A single-cell atlas of the tumor and immune ecosystem of human breast cancer.Cell2019;177:1330-45.e18 PMCID:PMC6526772

[103] Kim IS,Welte T.Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms.Nat Cell Biol2019;21:1113-26 PMCID:PMC6726554

[104] Naik A.Lactate metabolism and immune modulation in breast cancer: A focused review on triple negative breast tumors.Front Oncol2020;10:598626 PMCID:PMC7725706

[105] Pilon-Thomas S,El-Kenawi AE.Neutralization of tumor acidity improves antitumor responses to immunotherapy.Cancer Res2016;76:1381-90 PMCID:PMC4829106

[106] Pötzl J,Bankel L.Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-γ and induces NK cell-dependent lymphoma control without other immunotherapies.Int J Cancer2017;140:2125-33

[107] O'Sullivan D,Pearce EJ.Metabolic interventions in the immune response to cancer.Nat Rev Immunol2019;19:324-35

[108] Nanda R,Dees EC.Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol2016;34:2460-7 PMCID:PMC6816000

[109] Adams S,Rugo HS.Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.Ann Oncol2019;30:397-404

[110] Szekely B,Li X.Immunological differences between primary and metastatic breast cancer.Ann Oncol2018;29:2232-9

[111] Hutchinson KE,Chang CW.Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts.Clin Cancer Res2020;26:657-68

[112] Nanda R,Yau C.Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.JAMA Oncol2020;6:676-84 PMCID:PMC7058271

[113] Schmid P,Pusztai L.Pembrolizumab for early triple-negative breast cancer.N Engl J Med2020;382:810-21

[114] Oncologic Drugs Advisory Committee (ODAC) Meeting Briefing Materials. Available from: https://www.fda.gov/media/145654/download. [Last accessed on 24 Mar 2021]

[115] Mittendorf EA,Barrios CH.Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.Lancet2020;396:1090-100

[116] Mittendorf EA,Zhang H.Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC). Proceedings of the 2020 Virtual San Antonio Breast Cancer Symposium. 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; 2021.

[117] Gianni L,Egle D.Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Proceedings of the 2019 San Antonio Breast Cancer Symposium. 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; 2020.

[118] Voorwerk L,Horlings HM.Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.Nat Med2019;25:920-8

[119] Loibl S,Burchardi N.A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.Ann Oncol2019;30:1279-88

[120] Cortés J,Im S.KEYNOTE-119: phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (MTNBC).Ann Oncol2019;30:v851-934

[121] Dirix LY,Jerusalem G.Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study.Breast Cancer Res2018;167:671-86 PMCID:PMC5807460

[122] Galluzzi L,Kepp O.Immunological effects of conventional chemotherapy and targeted anticancer agents.Cancer Cell2015;28:690-714

[123] Schmid P,Rugo HS.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.N Engl J Med2018;379:2108-21

[124] Emens LA,Barrios CH.IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer.Ann Oncol2020;31:S1148

[125] Miles DW,André F.Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC).Ann Oncol2020;31:S1147-8

[126] Rugo HS,Cescon DW.Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer.San Antonio Breast Cancer Symposium2020;

[127] Cortés J,Rugo HS.KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.J Clin Oncol2020;38:1000

[128] Huang X,Guo H.Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.Hum Pathol2020;108:42-50

[129] Lee SE,Lim SD.Concordance of Programmed death-ligand 1 expression between SP142 and 22C3/SP263 assays in triple-negative breast cancer.J Breast Cancer2020;23:303-13 PMCID:PMC7311361

[130] Noske A,Wagner DC.A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.Histopathology2021;78:567-77

[131] Gonzalez-Ericsson PI,Sua LF.The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.J Pathol2020;250:667-84

[132] Samstein RM,Shoushtari AN.Tumor mutational load predicts survival after immunotherapy across multiple cancer types.Nat Genet2019;51:202-6 PMCID:PMC6365097

[133] Barroso-Sousa R,Pernas S.Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer.Clin Cancer Res2020;26:2565-72 PMCID:PMC7269810

[134] Lu S,Rimm DL.Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis.JAMA Oncol2019;5:1195-204 PMCID:PMC6646995

[135] Keren L,Marquez D.A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed Ion beam imaging.Cell2018;174:1373-87.e19 PMCID:PMC6132072

[136] Schürch CM,Barlow GL.Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. 2020;182:1341-59.e19. PMCID:PMC7479520

[137] Coombes RC,Salari R.Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence.Clin Cancer Res2019;25:4255-63

[138] Bratman SV,Iafolla MAJ.Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.Nat Cancer2020;1:873-81

[139] Volovat SR,Hordila I.MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: A review.Front Oncol2020;10:526850 PMCID:PMC7716774

[140] Piña-Sánchez P,Ruiz-Tachiquín M.Circulating microRNAs and their role in the immune response in triple-negative breast cancer.Oncol Lett2020;20:224 PMCID:PMC7499949

[141] Yu Y,Li A.Association of long noncoding RNA biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer.JAMA Netw Ope2020;3:e202149 PMCID:PMC7139278